modality directory

combination therapy clinical trial intelligence

Trials are included when the normalized modality field matches this therapeutic modality. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

modality

Association rule

normalized field

NCT03890952

Source recordAI-normalized

A Phase II Open Label, Two-armed Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma

This Phase II study investigates the combination of Nivolumab, a PD-1 inhibitor, and Bevacizumab, an angiogenesis inhibitor, in patients with recurrent glioblastoma (GBM). The market for glioblastoma treatments is significant, with a high unmet need for effective therapies due to the aggressive nature of the disease and poor prognosis. The combination therapy aims to enhance anti-tumor activity by leveraging immune modulation and vascular normalization. Competitive implications include potential differentiation from existing therapies, particularly in biomarker-driven patient selection. Diligence considerations should focus on the safety profile, efficacy data, and the potential for subsequent regulatory approvals based on the outcomes of this trial.

AI analysis

Indication: Recurrent Adult Brain Tumor

Modality: combination therapy

Target: PD-1 pathway modulation and angiogenesis inhibition via Nivolumab and Bevacizumab.

Sponsor: Ulrik Lassen

Source URL: ClinicalTrials.gov

Source updated: Jul 24, 2025

Ingested: Jun 12, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by modality_normalized: combination therapy

View original source fields

Condition raw: Recurrent Adult Brain Tumor

Condition normalized: Recurrent Adult Brain Tumor

Modality raw: combination therapy

Modality normalized: combination therapy

Target raw: PD-1 pathway modulation and angiogenesis inhibition via Nivolumab and Bevacizumab.

Target normalized: PD-1 pathway modulation and angiogenesis inhibition via Nivolumab and Bevacizumab.

Open report

NCT06433557

Source recordAI-normalized

A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children With Achondroplasia

This proof-of-concept trial is being conducted to evaluate the efficacy, safety and tolerability of combination treatment with navepegritide and lonapegsomatropin administered as separate subcutaneous (SC) injections once weekly in children with achondroplasia (ACH) aged 2 to 11 years.

AI analysis

Indication: Achondroplasia

Modality: combination therapy

Target: Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections

Sponsor: Ascendis Pharma Growth Disorders A/S

Source URL: ClinicalTrials.gov

Source updated: Feb 18, 2026

Ingested: Jun 11, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by modality_normalized: combination therapy

View original source fields

Condition raw: Achondroplasia

Condition normalized: Achondroplasia

Modality raw: combination therapy

Modality normalized: combination therapy

Target raw: Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections

Target normalized: Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections

Open report

NCT05232994

Source recordAI-normalized

Use of Combination Metformin and Esomeprazole in Preterm Pre- Eclampsia: Randomized Controlled Trial

A recent randomized controlled trial by Cluver et al included 180 women with preterm pre-eclampsia between 26+0 to 31+6 weeks' gestation undergoing expectant management: 90 were randomised to extended release metformin and 90 to placebo. Investigators found that extended release metformin (3g daily) can prolong gestation in women with preterm pre-eclampsia. Combination metformin and esomeprazole has shown promise in the treatment of preeclampsia as both agents reduce placental and endothelial secretion of soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin, and reduce endothelial dysfunction.

AI analysis

Indication: Preeclampsia Severe

Modality: combination therapy

Target: Esomeprazole 20mg

Sponsor: Christiana Care Health Services

Source URL: ClinicalTrials.gov

Source updated: Feb 10, 2023

Ingested: Jun 11, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by modality_normalized: combination therapy

View original source fields

Condition raw: Preeclampsia Severe, Preeclampsia Second Trimester, Preterm Birth Complication

Condition normalized: Preeclampsia Severe, Preeclampsia Second Trimester, Preterm Birth Complication

Modality raw: combination therapy

Modality normalized: combination therapy

Target raw: Esomeprazole 20mg

Target normalized: Esomeprazole 20mg

Open report

NCT05786352

Source recordAI-normalized

Outcomes of Enhanced Recovery After Surgery (ERAS) vs. Standard of Care in Cesarean Deliveries: A Randomized-Controlled Trial

In recent years, a set of evidence-based recommendations called Enhanced Recovery After Surgery (ERAS) is being applied for care of cesarean sections. The effectiveness of ERAS in reducing the length of hospitalization, postoperative complications, the need for analgesics right away after surgery, and the financial cost in the context of cesarean sections has been shown in several studies. There is strong evidence that following ERAS protocols aids postoperative recovery positively. This will be a randomized trial to determine if there is a difference regarding adverse maternal outcomes between ERAS group and standard of care.

AI analysis

Indication: Cesarean Section Complications

Modality: combination therapy

Target: ERAS protocol

Sponsor: Zeynep Kamil Maternity and Pediatric Research and Training Hospital

Source URL: ClinicalTrials.gov

Source updated: Mar 27, 2023

Ingested: Jun 09, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by modality_normalized: combination therapy

View original source fields

Condition raw: Cesarean Section Complications, ERAS

Condition normalized: Cesarean Section Complications, ERAS

Modality raw: combination therapy

Modality normalized: combination therapy

Target raw: ERAS protocol

Target normalized: ERAS protocol

Open report

NCT06465186

Source recordAI-normalized

Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis

Efinopegdutide is being developed by Merck Sharp & Dohme LLC for the treatment of compensated cirrhosis secondary to MASH, a condition with significant unmet medical need and increasing prevalence due to rising obesity and diabetes rates. The global market for therapies targeting liver diseases, particularly NASH/MASH, is projected to grow substantially, with numerous competitors also in development. Successful outcomes from this trial could position Merck favorably in a competitive landscape, potentially leading to a first-in-class designation if efinopegdutide demonstrates superior efficacy and safety. Diligence should focus on the regulatory pathway, potential market access challenges, and the evolving competitive landscape as other candidates progress through clinical trials.

AI analysis

Indication: Non-alcoholic Fatty Liver Disease

Modality: combination therapy

Target: Efinopegdutide (MK-6024) targets metabolic dysfunction-associated steatohepatitis (MASH) by potentially reducing liver fat, inflammation, and fibrosis.

Sponsor: Merck Sharp & Dohme LLC

Source URL: ClinicalTrials.gov

Source updated: Mar 02, 2026

Ingested: Jun 09, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by modality_normalized: combination therapy

View original source fields

Condition raw: Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis

Condition normalized: Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis

Modality raw: combination therapy

Modality normalized: combination therapy

Target raw: Efinopegdutide (MK-6024) targets metabolic dysfunction-associated steatohepatitis (MASH) by potentially reducing liver fat, inflammation, and fibrosis.

Target normalized: Efinopegdutide (MK-6024) targets metabolic dysfunction-associated steatohepatitis (MASH) by potentially reducing liver fat, inflammation, and fibrosis.

Open report

NCT03739736

Source recordAI-normalized

Tuberculosis Reduction Through Expanded Anti-retroviral Therapy and Screening of Active TB Project

The TREATS project aims to evaluate the impact of a combined TB/HIV intervention on TB incidence and prevalence in communities in Zambia and South Africa. It builds on the HPTN 071 (PopART) trial, focusing on population-level screening for TB and universal testing and treatment for HIV. The project seeks to provide definitive evidence for public health policy on TB control and prevention strategies.

AI analysis

Indication: Tuberculosis

Modality: combination therapy

Target: Tuberculosis (TB) and HIV co-infection

Sponsor: London School of Hygiene and Tropical Medicine

Source URL: ClinicalTrials.gov

Source updated: Feb 25, 2021

Ingested: May 23, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by modality_normalized: combination therapy

View original source fields

Condition raw: Tuberculosis

Condition normalized: Tuberculosis

Modality raw: Tuberculosis

Modality normalized: combination therapy

Target raw: Tuberculosis (TB) and HIV co-infection

Target normalized: Tuberculosis (TB) and HIV co-infection

Open report

NCT05761899

Source recordAI-normalized

A First-In-Human Clinical Trial of Lentiviral-mediated CSF2RA Gene Transfer/Pulmonary Macrophage Transplantation Therapy of Hereditary Pulmonary Alveolar Proteinosis

The major goal of this study is to evaluate a new type of cell transplantation therapy for individuals with hereditary PAP, study a new treatment that may be useful for treatment of other diseases, and research mechanisms that drive the development and function of lung macrophages.

AI analysis

Indication: Hereditary Pulmonary Alveolar Proteinosis

Modality: combination therapy

Target: Gene-Corrected Macrophages administered by bronchoscopic instillation

Sponsor: Children's Hospital Medical Center, Cincinnati

Source URL: ClinicalTrials.gov

Source updated: Dec 19, 2025

Ingested: May 21, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by modality_normalized: combination therapy

View original source fields

Condition raw: Hereditary Pulmonary Alveolar Proteinosis

Condition normalized: Hereditary Pulmonary Alveolar Proteinosis

Modality raw: combination therapy

Modality normalized: combination therapy

Target raw: Gene-Corrected Macrophages administered by bronchoscopic instillation

Target normalized: Gene-Corrected Macrophages administered by bronchoscopic instillation

Open report